Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Antibodies sites

An example of an immunoassay format is shown in Figure 3. This immunoassay format relies on partial saturation of the solid-phase antibody (Ab) by the antigen (Ag) and on its competition with the labeled antigen (Ag-L) for the available antibody sites. At low antibody and tracer concentrations the sensitivity of... [Pg.532]

Romano EL, Romano M. Staphyloccal protein A bound to colloidal gold a useful reagent to label antigen-antibody sites for electron microscopy. Immunochemistry 1977 14 711-715. [Pg.274]

In the last 5 years, catalytic antibodies have been generated for several reaction types, including the various types of hydrolysis, transesterification, amide bond formation, /3-elimination, cycloreversion, transacylation, redox reactions, E-Z isomerization, epoxidation, and Diels-Alder reactions. For more information on these and other recent developments, such as semi-synthetic antibodies, site-directed mutagenesis, and the bait-and-switch strategy, the reader should consult the appropriate authorities (Schultz, 1988, 1989a,b Benkovic et al., 1990 Janda et al., 1990, 1991 Janjic and Tramontano, 1990 Lerner et al., 1991). [Pg.59]

Since, both the radioactive and non-radioactive antigens (haptens) are more or less chemically and immunochemically the same, they will eventually compete for the limited number of antibody sites available thus, the amount of radioactivity that ultimately combines with the antibody will be an inverse function of the amount of unlabelled hapten competing for these sites,... [Pg.492]

Antibody Site 1 Site 2 Site 3 Site 4 Site 5 Mb... [Pg.47]

The absorbance of tube 1 is greater because there is no analyte introduced into the tube. All of the antibody sites are occupied by the conjugated enzyme and the absorbance is, as a result, more intense. [Pg.427]

Figure 19-13 illustrates the principle of an enzyme-linked immunosorbent assay, abbreviated ELISA in biochemical literature. Antibody 1, which is specific for the analyte of interest (the antigen), is bound to a polymeric support. In steps 1 and 2, analyte is incubated with the polymer-bound antibody to form a complex. The fraction of antibody sites that bind analyte is proportional to the concentration of analyte in the unknown. The surface is then... [Pg.411]

Roholt, O.A., Friedenson, B., Radzimski, G., Pressman, D. (1973). A light chain tyrosyl sequence in the antibody site of a rabbit anti-p-azobenzoate antibody. J. Immunol. Ill, 1367-1375. [Pg.87]

To a solution of known titre antiserum is added a known concentration of radioactive or tracer hapten (antigen) and an aliquot of the plant extract. There will be a competition of the labelled hapten (added) and unlabelled (plant extract) hapten for the fixed number of antibody sites (antiserum of known titre) and this results in some of the labelled hapten being bound while the remainder remains free. The distribution of the radioactive hapten between the free and bound state will be a function of the amount of unlabelled hapten present in the assay tube. [Pg.347]

After the incubation, the unbound molecules are washed away, leaving behind the bound ones, anchored onto the antibody sites. Now a clear solution of a colorforming reagent (chromogenic substrate) such as, 3,3, 5,5 -tetramethylbenzidine is added to the mixture. The enzyme conjugate, bound to antibody sites on the wall, reacts with the chromogenic substrate forming a blue color. The enzyme catalyzes the transformation of the substrate into a product which reacts with the... [Pg.109]

A brief description of techniques used in EIA follows. The various assays have been classified as either competitive or noncompetitive assays, depending on whether or not the technique involves a reaction step in which unlabeled and labeled antigen compete for a limited number of antibody sites (competitive assay) or whether the antigen (or antibody) to be measured is first allowed to react with antibody (antigen) on a solid phase followed by measurement of the binding of enzyme-labeled immune reactant (noncompetitive assay)... [Pg.420]

The problem of antibody complementarity thus resolves itself into the generation of different-shaped receptor sites upon a constant framework by substitution of sequences of one set of CDR of each chain by another. This has led to several attempts to construct models of antibody sites of a different specificity from the known structures. [Pg.37]

Antigen excess All antibody sites are saturated by antigen. Triplets (2 antigen + 1 antibody) are maximum size attained by particles. No precipitate is formed. [Pg.224]

A typical consequence of this relation 17.9 is the non-linearity of the experimental curve when the concentrations are plotted along the abscissa and at the ordinate the percent absorbance of the solution relative to the reference obtained with the blank (C=0). This reference is obtained with the blank (all of the antibody sites are, in this case, occupied by the conjugated enzyme). [Pg.429]

Fig. 4 Antibody immobilization in a limited-reagent assay format. The antibody is immobilized onto the solid-phase support. Labeled antigen and sample are introduced, and they compete with one another to form immunocomplex (Ab-Ag or Ab-AgE) with the limited antibody sites on the solid-phase support. After washing, the substrate is added to produce the detecting product. The antibody unoccupied by the sample analyte is measured as the concentration increases, the signal responses decreases. Fig. 4 Antibody immobilization in a limited-reagent assay format. The antibody is immobilized onto the solid-phase support. Labeled antigen and sample are introduced, and they compete with one another to form immunocomplex (Ab-Ag or Ab-AgE) with the limited antibody sites on the solid-phase support. After washing, the substrate is added to produce the detecting product. The antibody unoccupied by the sample analyte is measured as the concentration increases, the signal responses decreases.

See other pages where Antibodies sites is mentioned: [Pg.21]    [Pg.31]    [Pg.71]    [Pg.45]    [Pg.141]    [Pg.162]    [Pg.339]    [Pg.21]    [Pg.101]    [Pg.354]    [Pg.237]    [Pg.512]    [Pg.176]    [Pg.34]    [Pg.167]    [Pg.1527]    [Pg.256]    [Pg.588]    [Pg.607]    [Pg.5]    [Pg.12]    [Pg.15]    [Pg.44]    [Pg.61]    [Pg.230]    [Pg.19]    [Pg.127]    [Pg.134]    [Pg.351]    [Pg.525]    [Pg.260]    [Pg.316]   
See also in sourсe #XX -- [ Pg.277 , Pg.520 ]

See also in sourсe #XX -- [ Pg.17 ]




SEARCH



ARM complexes for In vitro display and evolution of antibody combining sites

Affinity labeling, of antibody combining sites

Anti-DNP antibody binding site

Antibodies active sites

Antibodies antigen-binding sites

Antibodies antigenic determinant sites

Antibodies binding site calibration

Antibodies effector sites

Antibodies site-directed conjugation

Antibody binding sites

Antibody combining site chemical modification

Antibody combining site crystallography

Antibody combining site, mimicry

Antibody-combining site

Antibody-combining site modification

Antigenic sites monoclonal antibodies against

Catalytic antibody antigen-binding sites

DNA replication site, mapping in situ fluorescent labeling with antibody

Dynamics of anti-DNP Antibody Binding Site

Site-directed antibodies

Site-directed conjugation of antibody molecules

Site-directed mutagenesis, catalytic antibodies

The IgE Antibody Combining Site

© 2024 chempedia.info